Beyond cDC1: Emerging Roles of DC Crosstalk in Cancer Immunity

Rajkumar Noubade*, Sonia Majri-Morrison and Kristin V. Tarbell

Department of Inflammation and Oncology, Amgen Research, Amgen Inc., South San Francisco, CA, United States

Dendritic cells (DCs) efficiently process and present antigens to T cells, and by integrating environmental signals, link innate and adaptive immunity. DCs also control the balance between tolerance and immunity, and are required for T-cell mediated anti-tumor immunity. One subset of classical DCs, cDC1, are particularly important for eliciting CD8+ T cells that can kill tumor cells. cDC1s are superior in antigen cross-presentation, a process of presenting exogenous antigens on MHC class I to activate CD8+ T cells. Tumor-associated cDC1s can transport tumor antigen to the draining lymph node and cross-present tumor antigens, resulting in priming and activation of cytotoxic T cells. Although cross-presenting cDC1s are critical for eliciting anti-tumor T cell responses, the role and importance of other DC subsets in anti-tumor immunity is not as well-characterized. Recent literature in other contexts suggests that critical crosstalk between DC subsets can significantly alter biological outcomes, and these DC interactions likely also contribute significantly to tumor-specific immune responses. Therefore, antigen presentation by cDC1s may be necessary but not sufficient for maximal immune responses against cancer. Here, we discuss recent advances in the understanding of DC subset interactions to maximize anti-tumor immunity, and propose that such interactions should be considered for the development of better DC-targeted immunotherapies.

Keywords: dendritic cells, cDC1, cDC2, crosstalk, cancer immunity

INTRODUCTION

The interaction between various myeloid and lymphoid cell populations is crucial to initiate and orchestrate a robust anti-tumor response. By processing tumor associated antigens (TAAs) and migrating to draining lymph nodes (dLN), where T cell priming occurs, dendritic cells (DCs) are considered the most potent professional antigen presenting cells (APCs) to elicit adaptive anti-tumor immunity (1). In addition to presenting antigens, DCs use soluble molecules such as cytokines and chemokines as well as direct cell-cell contacts to prime and activate TAA-specific T cells. DCs were discovered by Ralph Steinman and Zanvil Cohn in 1973 as an APC population, distinct from macrophages, that initiate adaptive immune responses (2). As a result of more recent deep-phenotyping, DCs are now recognized to be a heterogeneous population comprising several subsets distinguished by their development, phenotypic differences, localization, and functional specialization (2–6). This functional specialization of each subset allows DCs to initiate distinct immune responses in different immunological contexts (7). Here, we review literature supporting the hypothesis that, although one DC subset, conventional DC1(cDC1), has been shown to be crucial for anti-tumor immunity, multiple DC subsets, and interactions with other cells are needed for maximal responses.


DC Subsets Are Functionally Specialized

DCs are broadly classified as classical (or conventional) DCs (cDCs) and plasmacytoid DCs (pDCs), each with specialized functions. cDCs, specialized in antigen presentation to naïve T cells can be further segregated into cDC1s and cDC2s, excelling in MHC class I- and class II-mediated antigen-presentation, respectively (3, 6, 8–10). cDCs are found both as lymphoid and non-lymphoid tissue cells, the latter of which can migrate via the lymph to dLN to present tissue-derived antigens (3, 11). cDC1s, present at lower frequency compared to cDC2s, are identified by the expression of XCR1 (12), and in humans, also by the expression of CD141 (BDCA3) (5, 13, 14). cDC1s possess specialized mechanisms to mediate efficient antigen recognition, antigen transport to appropriate endosomal compartments and subsequent processing for the presentation to CD8 T cells in a process known as cross-presentation (15–18). cDC1s can also activate CD4 T cells through MHC class II antigen presentation and can polarize activated CD4 T cells toward a Th1 phenotype through the secretion of IL-12 (19).

cDC2s are specialized in MHC class II-mediated antigen presentation and are the most efficient APCs for activation and expansion of CD4 T cells (5, 13, 20). They are the most frequent DC population present in blood, lymphoid organs and tissues and promote a wide range of immune responses including Th1, Th2, and Th17 in specific contexts (13, 19, 21–25). Human cDC2s can be identified by their preferential expression of CD1c (BDCA1) and CD172a (SIRPα) (26). cDC2s are more heterogenous than cDC1s, and express various receptors that enable them to respond to broad spectrum of microbial products (22, 26–28). A subset of Notch2-dependent cDC2s specializes in IL-23 production and contributes to innate defense and adaptive immune responses (27, 29).

pDCs, distinguished by their ability to produce large amounts of type 1 IFN upon viral infection (30–33) are identified, in humans, by the expression of surface markers CD303 (BDCA-2), CD304 (BDCA-4/Neuropilin) and CD123 (5, 13). They are present mainly in lymphoid organs and can migrate to the LN through blood circulation (5, 34). Mature pDCs can also act as APCs and have distinct regulation of MHC class II surface expression that results in sustained membrane peptide-MHC complex and antigen presentation (30). A heterogeneity of pDCs is also described in terms of their ability to produce type I IFN and/or antigen presentation (35, 36).

Another related but developmentally distinct population, derived from monocytes, termed monocyte DCs (moDC) upregulates certain functional properties of DCs in some contexts and express tumor necrosis factor (TNF)-α and intracellular nitric oxide synthase (iNOS) (37). More commonly, the term moDCs refers to monocyte isolated from human peripheral blood mononuclear cells (PBMC) that are in vitro differentiated in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4 into cells sharing several phenotypic and functional features of DCs (26, 38, 39). moDCs are the most common in vitro model of DCs, yet are quite heterogeneous in both mouse and human, with unclear relationship to in vivo cell populations (40–42).

All DC subsets, including cDCs and pDCs, are found in the tumor microenvironment (TME) (30, 43–47) and among the cDCs, the cDC2s outnumber cDC1s, with cDC1s being the rarest APCs within the TME (43, 48). The role of pDCs in tumor immunity remains elusive and contradictory. Similarly, the precise role of cDC2s in anti-tumor immunity has been difficult to delineate due to lack of proper genetic tools. On the contrary, mounting evidence suggests cDC1s to be the critical antigen presenting DC subset for the generation of anti-tumor immunity. Here we summarize data supporting the importance of cDC1s in anti-tumor immunity, and then review the recent literature that documents DC crosstalk being necessary for effective immune responses, in other contexts such as anti-viral immune responses, and apply these principles to tumor immunity.

cDC1s Are Necessary for Anti-tumor Immunity

Since MHC class I molecules are expressed by every cell in the body (not just infected cells and cancer cells), to avoid bystander killing of healthy cells by CTLs, extracellular antigens do not enter the MHC class I-loading machinery (15, 18). Therefore, to generate an immune response, cancer cell antigens need special processing in APCs to be presented to naïve CD8 T cells. Moreover, naïve CD8 T cells primarily circulate through secondary lymphoid organs (15). Hence, cancer antigens must be brought to secondary lymphoid organs to be presented to naïve CD8 T cells. cDC1s fulfill both functions by patrolling tumor tissues, and by capturing, processing and presenting tumor-antigens on their surface through MHC class I molecules via antigen cross-presentation. cDC1s then migrate to dLN and deliver peptide/MHC class I signal to CD8 T cells which leads to their activation and the initiation of an immune response against tumor cells (15, 18).

Although other cell types have been reported to cross-present antigens (11, 49), this specialized function is mostly attributed to the cDC1 subset, owing to their unique adaptations of subcellular molecular machinery and vesicular trafficking (15, 18). Such adaptations include efficient antigen uptake of dying cells, delivery of cell-associated antigen to early endosomes, (15, 50–52), efficient phagosome-to-cytosol export of an ingested antigen possibly aided by ER-derived translocons and ER-associated degradation (ERAD) components such as Sec61, Derlin, p97 ATPase, Sec22 (15, 53–55), lower expression of lysosomal proteases (50) and antagonizing their degradative functions via NOX2-mediated ROS generation (56–60). The end result of such lower proteolysis, and therefore, increased antigen retention in cDC1s, is eventually an enhanced ability to carry the antigen all the way from peripheral tissues where the antigen is captured, to the dLN, where priming and activation of CD8 T cells occurs (56). The importance of cDC1s’ ability to cross-present antigen in its immune functions is recently demonstrated using Wdfy4-deficient mice, which selectively lack cross-presentation (61).

Beyond their role in antigen cross-presentation, cDC1s are the major source of IL-12 production and thus influence anti-tumor immunity by activating NK cells and driving CD4 T cell responses toward Th1 responses (19, 62–64).
The critical role of cDC1s in anti-tumor immunity has been shown using mice deficient in basic leucine zipper transcription factor ATF-like 3 (Batf3), a transcription factor required for cDC1 differentiation (65). Batf3 knockout mice lack cDC1 cells but not other APCs and display impaired anti-tumor immunity in several models (43, 65–68). Expansion and activation of cDC1s using fms-related tyrosine kinase 3 ligand (Flt3L) and poly I:C leads to significant enhancement of antitumor responses (45). Immunotherapies such as PD1/PD-L1 blockade or CD137 agonists are ineffective in Batf3-deficient mice, highlighting the crucial role cDC1s in tumor immunity (68, 69). Furthermore, tumor-resident cDC1s are required for trafficking of adoptively transferred CD8T cells into tumors through their ability to produce CXCL9 and CXCL10 (67, 70). DC-specific deletion of Sec22b leads not only to impaired cross-presentation of TAAs and reduced anti-tumor immune responses but also abolishes the efficacy of anti-PD1 therapy (53). In humans, the presence of cDC1s within the TME is associated with better prognosis and response to immunotherapy. Analysis of the cancer genome atlas (TCGA) dataset shows that a higher ratio of a cDC1 gene signature to a signature of all other myeloid cells (including monocyte/macrophage, and not just other DC subsets) is associated with better prognosis across human tumors (44, 71). Abundance of CD8T cells positively correlates with cDC1 markers in pancreatic tumors (70). Taken together, these data show that cross-presenting cDC1s are crucial and necessary for the generation of an effective anti-tumor immunity.

**cDC1 Are Not Sufficient for Maximal Anti-tumor Immunity: Potential Roles of Other DC Subsets**

Tumor immunology is built upon the tenet that cytotoxic CD8 T cells (CTLs) eliminate tumor cells (72) and the prevailing dogma is that cDC1s are the most potent APCs for the CTL response against tumor. Because of the strong evidence for the importance of cDC1 in tumor immunity, as presented in the previous section, in one scenario it is possible that cDC1s are the sole DC subset sufficient for optimal anti-tumor CTL generation through antigen presentation via MHC class I as well as MHC class II (Figure 1A). A major driver of the current dogma is the studies conducted in mice genetically manipulated to lack cDC1 such as Batf3-deficient or Zbtb46-Cre mice. However, these tools are imperfect. For example, Batf3 is expressed in cDC2 and effector CD4T cells (65, 73) and Zbtb46 is also expressed in DC2s as well as in endothelial cells (74–76), raising the possibility of contributions from additional DC subsets and other cell types. Hence, it is not clear whether the cDC1 subset alone is sufficient to provide the maximal immunity against tumor. Recent evidence in non-tumor settings has demonstrated that cDC1s require significant contributions from other DC subsets and are not sufficient for an optimal CTL response (77–79), pointing toward a role for the other cells in shaping a robust and durable anti-tumor immunity.

Therefore, we describe a second scenario that includes possible roles of other DC subsets for a more robust anti-tumor immunity, directly and indirectly (Figure 1B). This scenario incorporates recent findings of spatiotemporal segregation of cDC1 and cDC2 activation within dLN to activate CD8 and CD4T cells, respectively, during antiviral response. This robust CTL response requires interactions between multiple DC subsets, including cDCs and pDCs in a two-step priming process (77–79). Even though these responses are context dependent and are observed in anti-viral response, the general principals remain the same in anti-tumor immune response. Accordingly, in this scenario, the tumor-derived cDC1 primes CD8T cells while tumor-derived cDC2 activates CD4T cells in the first step of the CTL priming process and then in the second step, the activated CD4T cells licenses a LN-resident cDC1 to relay the help for CTLs. Contributions of activated CD4T cells to anti-tumor immunity can be more than just providing the help to CTLs, but also include activation of NK cells and macrophages through IFN-γ, modulation of tumor stroma and angiogenesis or direct cytolytic effects (80–83).

Additionally, during the two-step priming process, pDCs are recruited to cDC1–CD8T cell priming sites, providing critical licensing signal to cDC1s through type 1 IFN. In this regard, lack of type 1 IFN receptor in cDC1s impairs their ability to
reject tumors (84, 85). Furthermore, pDCs are usually weak APCs in the absence of activating signals but direct antigen presentation and T cell stimulation by pDCs has been described (30, 86). In fact, adoptive transfer of tumor-antigen-loaded pDCs induced potent anti-tumor T cell responses in melanoma patients (87), suggesting the possibility of anti-tumor immunity directly through APC functions by pDCs.

In the following sections, we mainly focus on this latter scenario of non-synchronous activation events by cDC1s and cDC2s and the reorganization of pDCs to the sites of CTL priming to describe the crosstalk between DC subsets and propose an integrated model of multi-DC subsets, multi-cell type interactions in achieving full-strength CTL responses in anti-tumor immunity.

Crosstalk Between DC Subsets

One of the goals of cancer immunotherapy is to promote tumor-antigen specific T cell responses. The current data supports the notion that cDC1s are well-suited for this purpose and that they are usually necessary for the generation of an anti-tumor response. However, as discussed below, they may not be sufficient for full-strength anti-tumor cytotoxic T cell responses and interactions with other DC subsets contribute to this process. In the following sections, we will review the interactions between each DC subsets separately.

CDC1-cDC2 Crosstalk

The two cDC subsets communicate not only through soluble mediators such as IL-12 but also through a third cell viz., activated CD4 T cell. Even though both cDC subsets are adept in priming naïve T cells, cDC2s are more proficient in activating CD4 T cells than CD8 T cells while cDC1s are potent activators of CD8 T cells but present antigen to CD4 T cells less efficiently, both in vitro and in vivo (8, 20, 43). However, recent literature demonstrates that robust and maximal induction of cytotoxic CD8 T cell responses against cell-associated antigens not only requires interactions with cDC1s, but also interactions involving cDC2s (77, 100). Intravital microscopy demonstrated that, in the dLN, the two cDC subsets exhibit differential localization wherein cDC1s are largely segregated to the T cell zone in deep paracortical regions and cDC2s are more peripherally distributed (78, 100–103) and that CD8 T cells cluster with cDC1s and CD4 T cells cluster with cDC2s during step one of two-step T cell priming event in anti-viral immunity (78, 100, 104), suggesting parallel activation of the two T cell subsets by two different cDCs in an asynchronous manner. Such differential localization of the cDC subsets into non-overlapping T cell regions is also reported in the spleen (105).

The peripheral DC subsets also exhibit different kinetics during their migration to dLN (106), with an implication that cDC2s might access CD4 T cells earlier. The CD4 T cell activated in the first step of the priming process, then gets recruited to LN-resident, XCR1+ cDC1 during the second step of the priming process and delivers help signals to that cDC1. The receiver-cDC1 then transmits the help signal to CD8 T cell activated in the first step, resulting in a robust expansion of highly effective CTLs. In this regard, it is well-established that, in the absence of CD4 T cell help, CD8 T cell responses are weaker and insufficient to generate long-lasting memory (107–109). The CD4 T cell help includes molecules such as CD40L expressed on CD4 T cells, that induces expression of costimulatory molecules including CD70, CD80, CD86, and cytokines such as IL-12, IL-15 by cDC1 (66, 110–112). The molecular nature of CD4 T cell help in shaping the CTL response is recently reviewed (104) and will not be discussed here in detail. Signaling though type
I IFN is critical for proper functioning of cDC1s (85) and cDC2s are one of the important sources of this cytokine, as shown by depletion of pDCs using anti-pDCA antibodies in Batf3-deficient mice (84).

cDC1s and cDC2s may also collaborate for optimal Th1 induction. In the context of leishmania infection, targeting antigen to either cDC1 or cDC2 can elicit IFNγ-producing T cells, but interestingly, the cDC2s require IL-12 produced by the cDC1s to induce Th1 responses, whereas the cDC1s induce Th1 responses via CD70, independent of IL-12 (19). Therefore, each DC subset provides different signals that can contribute to effector T cell responses. Among the activated CD4 T cells, Th1 cells excel in providing the help to cDC1s to prime and expand CTLs through of production large amounts of IFNγ (113), thus fostering an important crosstalk between the two cDCs.

The majority of the experimental data described above originates from studies in anti-viral immunity. However, where and how naïve cell-specific CD4 T cells get activated in a tumor setting is less clear. Lessons learnt on the importance of MHC class II-restricted CD4 T cell responses in autoimmune pathogenesis may shed light on this question in anti-tumor responses as well, since the anti-tumor response is essentially a self-specific response (114). The highest genetic risk for autoimmunity is conferred by HLA class II genes, with odds ratios >6, suggesting that CD4 T cell responses are necessary for immunity against self. In the context of autoimmunity, although some priming in the target tissue may occur (115–117), most studies suggest that self-specific CD4 T cells are first primed in the dLN, suggesting that a similar phenomenon might be happening in the generation of an anti-tumor immune response.

**Evidence for the Importance of Tumor-Derived cDC2s and Activation of CD4 T Cells in the Draining Lymph Node**

A large body of literature shows that naïve CD8 T cell activation for the generation of anti-tumor immunity occurs in dLN and is mediated by DCs (118–121). Interestingly, requirement of CD4 T cell help for optimal CD8 T cell effector functions in the context of tumor immunity is also well-documented, including the ability of CTLs to infiltrate the tumors (8, 119, 122–127). Non-helped CD8 T cells exhibit dysfunctional state with high expression of exhaustion markers in metastatic lung tumor model (127). In this regard, it is also well-established that the TME contains both cDC1 and cDC2 subsets (43–46). But importantly, both cDC1s and cDC2s scavenge tumor antigens (44) and migrate to dLN in a CCR7-dependent manner (46). Under right conditions, cDC2s can induce CD4 T cell activation in response to cell-associated antigen (51). Consistent with this, tumor-derived and dLN-derived cDC2s stimulate CD4 T cells more efficiently, ex vivo, in Lewis lung carcinoma model expressing ova as a model antigen (43). Furthermore, in this experimental setting, while cDC1 efficiently primed CD8 T cells, cDC2s are the most efficient activators of CD4 T cells. In addition, vaccination with the activated cDC2s reduced tumor growth, similar to that observed with cDC1s (43). Delivery of tumor antigen to cDC2 using dendritic cell immunoreceptor 2 (Dcir2) leads to significant anti-tumor effects in a mouse melanoma model (128). In a lung adenocarcinoma mouse model engineered to express MHC class II-restricted cytosolic antigen, activated cDC2 are observed both in the tumor and dLN and antigen-specific naive CD4 T are activated in the dLN (129). In breast cancer patients gene signature of cDC2s positively correlates with better survival, similar to that observed with cDC1s, (130) and MHC class II expression predicts response to anti-PD1/PD-L1 therapy in melanoma patients (131). Collectively, tumor-derived cDC2s are likely to contribute to CD4 T cell activation in the dLN.

**Integrated Model of DC Crosstalk in Tumor Draining Lymph Node**

The spatiotemporal nature of DC crosstalk suggests two distinct DC-mediated events for maximal CD8 T cell responses: one after the initial antigen capture and another after the antigen is transferred to dLN-resident cDC1 cells (8). This sequential CTL activation is demonstrated by the exclusive clustering of migratory cDC1s with CD8 T cells early on during the initiation of an antiviral immune response. Subsequent clustering of activated CD8 T cells with the LN-resident cDC1s acts as a platform for signal relay from pDCs and activated CD4 T cells (79). According to this “consecutive interaction” model (79, 112), the generation of maximal CTL response and therapeutic anti-tumor immunity requires a multicellular orchestration of events in the tumor dLN (Figure 2) wherein migratory cDC1s capture the antigen in tumors, migrate to the dLN and form the initial priming site to activate CD8 T cells. The activated CD8 T cells produce CCL3/CCL4 and XCL1 to mediate recruitment of CCR5+ pDCs and XCR1+ LN-resident cDC1s, respectively. The migratory cDC1s handoff antigen to resident cDC1s in a yet-to-be-described mechanism (44, 106). In parallel, migratory cDC2s that have captured the antigen also move from the tumor to dLN and activate CD4 T cells. The pDCs induce the maturation of newly recruited, LN-resident cDC1s and the activated CD4 T cells licenses them for superior CTL responses. The overall effect of such orchestration and functional-cooperativity of pathways between different DC subsets is the amplification of CTL responses against a given antigen, without potentially missing out on the critical help necessary for CTLs to function at their peak. In fact, vaccine-mediated induction of such coordinated efforts of multiple DC subsets is known to trigger sustained and potent CTL responses while inhibiting immunosuppressive pathways in preclinical models (132). Ex vivo analyses of individual DC subsets might fail to identify such cellular orchestration to appreciate the relative contribution of each interaction between the different DC subsets in the generation of potent immune response.

**DC Crosstalk in Tumors in situ**

Accumulating evidence suggest that cross-priming by tumor-resident cDC1 in situ is also an important phenomenon in the generation of an anti-tumor immune response. Local T cell priming and activation within tumors were observed in mice that lacked LN, or when T cell recirculation was blocked (133–135). Furthermore, intratumoral cDCs are required for the tumor regression achieved with adoptively transferred T
An integrated model of DC crosstalk for anti-tumor immunity. Outline of the multicellular orchestration of events that can contribute to a robust anti-tumor response. (Note: not all events happen in every context, and the order may also differ). (1) Intratumoral migratory-cDC1 and -cDC2s scavenge tumor-derived antigens and migrate to tumor dLN. (2) migratory-cDC2s (mig-cDC2) present MHC class II-restricted tumor antigen to CD4 T cells and induce expression of molecules such as CD40L. (3) these activated CD8 T cells produce XCL1 and CCL3/4 to draw in XCR1+LN-resident-cDC1s and CCR5+ pDCs to the site of initial priming. (5) Mig-cDC1s can hand-off antigen to the newly recruited, LN-resident-cDC1. (6) pDCs produce type I IFN to mature cDCs. (7) The licensed CTL with enhanced effector functions undergoes clonal expansion and moves to the tumor to induce tumor cell killing. (8) The activated CD8 T cells and NK cells can mediate further increase in cDC1 numbers by producing XCL1 and FLT3L.

cells in an experimental setting where migration of T cells to dLN was prevented (44). Moreover, tumor-resident cDC1s are the predominant sources of CXCL9 and CXCL10 and mediate recruitment effector T cells into the tumor (67). Similar to the events described for the dLN in the previous section, activated CD8 T cells could potentially orchestrate events in situ in the tumor where LN-like structures known as tertiary lymphoid structures (TLS) are present. A hallmark of TLS is the presence of high endothelial venules (HEVs) and expression of CCL19 and CCL21, the ligands for CCR7 (136, 137). DCs migrate in a CCR7-dependent manner (43, 45, 46, 138, 139). Moreover, well-organized TLSs contain B cell and T cells areas with mature DC subsets including cDCs and pDCs. Such organization makes TLS an ideal place to sustain proximity and the crosstalk between various subsets, and orchestrating local events required for maximal tumor immunity (135, 136). In fact, tumor-associated TLSs are functional structures capable of recruiting antigen-specific T cells and facilitating their activation through interactions with DCs (140). Interestingly, TLSs have been observed in several human tumors and their presence, particularly the ones containing high amounts of DCs and Th1 cells within the TLS, is associated with better prognosis (137, 141, 142) and increased TLS density is associated with strong infiltration of effector and memory CD8 T cells within the tumors (141), reflecting the importance of crosstalk between DC subsets and, CD4 help in increased CTL trafficking. Lung cancer patients with intratumoral CD8 T cells but no TLS had poor survival, indicating the necessity of their in situ education within the TLS for better effector functions (141, 143). In a metastatic lung tumor model, administration of TLR9 activator leads to CD8 T cell infiltration concurrent with TLS formation. The presence of TLS in this model was completely dependent on CD4 help (127). Taken together, these data suggest that TLSs promote DC crosstalk and anti-tumor immunity. Thus, induction of TLS provides another opportunity to promote communication between DC subsets to augment the magnitude of protective immunity, particularly against neoantigens that arise during the later phases of tumor progression (121). Moreover, induction of simultaneous trafficking and activation of cDCs and pDCs, using a vaccination strategy that combined DC subset-specific adjuvants (e.g., CpG-ODN and GM-CSF) leads to local accumulation of CD8 T cells and superior anti-tumor responses (132) suggesting that, even in the absence of TLS, evoking appropriate DC-crosstalk within the tumor tissue has the potential to boost superior CTL responses than targeting a single DC subset.

### Influence of DC Crosstalk With Other Cells in the TME on Anti-tumor Immunity

DCs can also engage with other immune cell types in the TME and lymphoid organs. Such interactions can enhance or dampen DC functions and anti-tumor immunity, depending on the cell types involved. For example, DCs interact with Treg cells, resulting in the suppression of CD8 T cell-mediated anti-tumor immunity (144). Two-photon laser-scanning microscopy analysis showed that Treg cells engage in prolonged physical interactions with DCs, six times longer than that of DC-cDC8 T cell interaction in tumor. This extended physical contact between Treg cells and DCs results in upregulation
of the immunosuppressive molecules such as IDO and lower maturation molecules on DC surface (144).

Interactions with other immune cell types such as natural killer (NK) cells with DCs can boost the immune response against tumors. It has long been established that, through the secretion of IL-12, cDC1s can license NK cells to kill tumor cells (145–147). However, recent studies have shown that NK cells can also influence DC functions in the context of tumors. In fact, NK cells produce XCL1 to recruit XCR1+ cDC1s to the TME (148). In addition, NK cells are one source of Flt3L within the tumor and dictate intratumoral accumulation of cDC1 cells by supporting DC survival, proliferation or development (71). Stimulation of NK cells with DC-derived factors such as IL-12, IL-15/IL-15Ra complex or contact–dependent interactions of OX40-OX40L augment NK cell functions to eliminate tumor cells (149–151). TCGA analysis suggests that NK cell/XCL1/cDC1 axis is associated with better survival in many cancer indications (148).

DCs also interact with NKT cells, the unconventional T lymphocytes expressing a semi-invariant T cell receptor (TCR) that recognize glycolipids presented by CD1d. (152). Although CD1d can be expressed by many hematopoietic cell types, DCs constitutively express CD1d and are the most potent APCs for exogenous glycolipids (153–155). The NKT cell ligand α-galactosylceramide (α-GalCer) acts as a potent in vivo adjuvant for DCs, resulting in increased expression of MHC class II and other costimulatory molecules (155). In addition, α-GalCer presented by DCs strongly activates NKT cells through CD40/CD40L interaction to induce IFN-γ production (156). Administration of α-GalCer was efficacious in preclinical tumor models (157) but not in patients (158), most likely due to soluble α-GalCer-induced anergy of NKT cells (159). Administration of α-GalCer, either soluble or loaded in DCs, is currently being explored to enhance anti-tumor immunity (160). Endogenous glycolipids are known to activate NKT cells (161) and CD1d expression is observed on tumor cells (162). In fact, the level of CD1d expression on tumor cells dictates NKT-mediated cytotoxicity (163).

Tumor-associated macrophages, in most carcinomas, are linked to poor prognosis primarily due to their immunosuppressive phenotype (164, 165). Macrophages produce IL-10 and in turn prevent IL-12 secretion of by DCs, resulting in dampened tumor-specific CD8 T cell activation (166). Among mononuclear phagocytes, monocyte-derived cells (including macrophages) are found at higher frequencies in tumors compared to DCs, and a higher monocyte-macrophage signature is associated with worse clinical prognosis (130, 167). These cells maintain a phenotype similar to in vitro M2 macrophages and contribute to the suppressive tumor microenvironment primarily via expression of anti-inflammatory mediators such as IL-10, TGF-β and IDO. Many of these signals dampen the ability of cDCs to present antigen in an immunogenic manner (164). However, in other contexts, macrophages can be inflammatory and effective APCs for eliciting T cell responses (168, 169). Thus, with the addition of the right signals, tumor macrophages have the potential to contribute to anti-tumor immunity.

Additionally, even though B cells have been described to play varied and often contrasting roles in the contexts of tumor immunity, emerging evidence suggests that B cells may also contribute to tumor immunity, both via antibody-mediated effects and by acting as APCs (170–172). Specifically, in terms of the crosstalk, DCs engage with B cells to promote their growth and differentiation, resulting in the production of antibodies. pDCs, through type I IFN production, can increase TLR7 expression and other activation markers on B cells (173). pDCs are specifically capable of inducing differentiation of activated B cells into Ig-secreting plasma cells through the secretion of type I IFN and IL-6 (174). Additionally, DCs dramatically enhance the secretion of IgG and IgA through the ligation of CD40 (175). B cells isolated from TLS-containing lung cancers showed significant antibody response against many TAAs (143, 176).

Finally, DC crosstalk with cancer cells has tremendous impact on the immune surveillance of the tumors. Cancer cells express several immunosuppressive factors such as PGE2, β-catenin and cytokines such as IL-10. PGE2 renders cDC1s unresponsive to XCL1 and CCL5 by downregulating XCR1 and CCR5 expression (148). β-catenin expression in cancer cells causes ATF3-mediated suppression of CCL4, the ligand for CCR5, leading to defective recruitment of cDC1 to the TME, and adversely affecting CD8 T cell priming against TAAs (177). Interestingly, PGE2 also induces the expression of β-catenin not only in tumor cells but also in stromal cells such as cancer associated fibroblasts (CAFs). CAFs respond to tumor-derived TNFα and IL-1β to secrete thymic stromal lymphopoietin (TSLP). TSLP is a strong driver of cDCs to activate Th2 CD4 T cells that are considered pro-tumorigenic (178). CAFs also produce stromal cell-derived factor 1 (SDF1) which drives cDCs toward tolerogenic DCs secreting IDO in a STAT3-dependent manner and promoting the recruitment and differentiation of Treg cells in tumors (179). However, co-targeting fibroblasts in combination with DC-based vaccine enhances the anti-tumor immune responses (180), suggesting that DC/stromal cell interactions can be manipulated to improve immunotherapies. Overall, with the property of bridging the innate and adaptive immune cells, DCs have a pivotal role in orchestrating an anti-tumor immune response by engaging interactions with many cell types within the TME.

Potential Therapeutic Applications of Tumor DC-Crosstalk

The field of cancer immunotherapy, energized by the effect of T cell checkpoint inhibitors (CPI) in some patients, is beginning to focus on ways to treat “cold” tumors that lack T cells which can be activated with an anti-PD1 or other CPI. There is a large unmet medical need to increase the proportion of patients who respond to immunotherapy. Enhancing innate immunity, and DC function in particular, is one way to make tumors “warmer” that has tremendous potential. To date, most cell-based DC cancer therapies have utilized moDCs and have shown limited efficacy (121, 181, 182). With our current knowledge of both the importance of cross-presenting cDC1s for tumor immunity and the plasticity of monocyte-derived cells, moDCs are likely not the best cell type to use
for inducing optimal clinical outcomes against cancer. Most studies show that moDCs have limited capacity for both cross-presentation and migration to draining LN compared to Batf3-dependent cells (43, 183). In addition, most monocyte-derived cells in the TME are immunosuppressive, and even if ex vivo moDCs can be activated to sustain cDC1-like properties, these are not likely maintained in the TME (121, 181). Therefore, moDC-based vaccines may not be the answer, and a new generation of DC-focused cancer immunotherapies are needed.

Increasing cDC1 function is one important goal, but as described here, some of this can occur indirectly via the cooperative interactions with other cells. In addition, both cDCs and pDCs have the potential to directly activate T cells that can kill cancer cells if exposed to the right activating signals (Figure 1B). Therefore, targeting maturation signals specifically to just cDC1s may not be the optimal therapy, and delivering signals that can enhance the function of all DC subsets may enhance efficacy and durability. For example, although tumor signals that can enhance the function of all DC subsets may to just cDC1s may not be the optimal therapy, and delivering 

REFERENCES

1. Worbs T, Hammerschmidt Si, Forster R. Dendritic cell migration in health and disease. Nat Rev Immunol. (2017) 17:30–48. doi: 10.1038/nri.2016.116
2. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med. (1973) 137:1142–62. doi: 10.1084/jem.137.5.1142
3. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Ann Rev Immunol. (2013) 31:563–604. doi: 10.1146/annurev-immunol-020711-074950
4. Cosenza H, Leserman LD, Rowley DA. The third cell type required for the cellular and molecular nature of tumor-specific CTL priming. J Exp Med. (2010) 207:1261–71. doi: 10.1084/jem.20092613
5. Dress RJ, Wong AY, Ginhoux F. Homeostatic control of dendritic cell numbers and differentiation. Immuno Cell Biol. (2018) 96:463–76. doi: 10.1111/icmb.12028
6. Theisen D, Murphy K. The role of cDC1s in vivo: CD8+ T cell priming through cross-presentation. F1000Res. (2017) 6:98. doi: 10.12688/f1000research.9997.1
7. Devi KS, Anandasapathy N. The origin of DCs and capacity for immunologic tolerance in central and peripheral tissues. Seminars Immunopathol. (2017) 39:137–52. doi: 10.1007/s00281-016-0602-0
8. Murphy TL, Grajales-Reyes GE, Xu W, Tussiwan R, Briseno CG, Iwata A, et al. Transcriptional control of dendritic cell development. Ann Rev Immunol. (2016) 34:93–119. doi: 10.1146/annurev-immunol-032713-122004
9. Nierkens S, Tej J, Janssen E, Adema GJ. Antigen cross-presentation by dendritic cell subsets: one general or all sergeants? Trends Immunol. (2013) 34:361–70. doi: 10.1016/j.it.2013.02.007
10. Scott CL, Soen B, Martens L, Skrypek N, Saelens W, Taminau J, et al. The transcription factor Zeb2 regulates development of conventional and plasmacytoid DCs by repressing Id2. J Exp Med. (2016) 213:897–911. doi: 10.1084/jem.20151715
11. Nierkens S, Tel J, Janssen E, Adema GJ. Antigen cross-presentation by dendritic cell subsets: the cellular and molecular nature of tumor-specific CTL, priming. The goal is to design therapies that build a site of sustained, immunostimulatory tumor-antigen presentation and increase the magnitude of anti-tumor immunity, so we can successfully treat a broader set of patients.

AUTHOR CONTRIBUTIONS
RN, SM-M, and KT designed and wrote the manuscript.

FINANCING
The authors, employees of Amgen Inc., declare that this study received funding from Amgen Inc. in its entirety. Amgen Inc. did not have a role in the study design.

ACKNOWLEDGMENTS
We thank Carlos Briseno, Michael Gonzalez, and Jackson G. Egen for critical reading of the manuscript and helpful discussions.
Lewis KL, Caton ML, Bogunovic M, Greter M, Grajkowska LT, Ng D, Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A, Villani AC, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, et al. Interferon-γ increases the expression of the IL-12p40 subunit on human dendritic cells by activation of microRNA-17-92. Immunity. (2013) 38:958–69. doi: 10.1016/j.immuni.2013.04.011

Persson EK, Uronen-Hansson H, Sennrich M, Rivollier A, Hagerbrand K, Persson EK, Uronen-Hansson H, Semmrich M, Rivollier A, Hagerbrand K, et al. High-dimensional phenotypic mapping of human dendritic cells reveals interindividual variation and tissue specialization. Immunity. (2017) 47:1037–50 e6. doi: 10.1016/j.immuni.2017.11.001

Alcantara-Hernandez M, Leylek R, Wagar LE, Engleman EG, Keler T, Alcantara-Hernandez M, Leylek R, Wagar LE, Engleman EG, Keler T, et al. The small GTPase Rac2 controls phagosomal alkalinization and antigen processing by dendritic cells. Cell. (2019) 179:1109–18. doi: 10.1016/j.cell.2019.04.016

Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by dendritic cells is critically dependent on the prior induction of an innate immune response against bacterial infection. Immunity. (2003) 19:59–70. doi: 10.1016/S1074-7613(03)00171-7

Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. (2007) 449:419–26. doi: 10.1038/nature06175

Helft J, Bottcher J, Chakraborty P, Zelenay S, Huotari J, Schraml BU, et al. GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c+ MHCIIC+ macrophages and dendritic cells. Immunity. (2015) 42:1197–211. doi: 10.1016/j.immuni.2015.05.018

Sander J, Schmidt SV, Ciovic B, McGovern N, Papantonopoulou O, Hardt AL, et al. Cellular differentiation of human monocytes is regulated by time-dependent interleukin-4 signaling and the transcriptional regulator NCoR2. Immunity. (2017) 47:1051–66 e12. doi: 10.1016/j.immuni.2017.11.024

Wu X, Brisenou CG, Durai V, Albring JC, Haldar M, Bagadia P, et al. MaCl gene tracing to distinct macrophages from a single lineage reveals dual identity of Langerhans cells. J Exp Med. (2016) 213:2533–65. doi: 10.1084/jem.201606000

Laoufi D, Keirse J, Morias Y, Van Overmeere E, Geeraerts X, Elkim Y, et al. The tumour microenvironment harbours ontogenetically distinct dendritic cell populations with opposing effects on tumour immunity. Nat Commun. (2017) 8:13720. doi: 10.1038/ncomms13720

Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. (2014) 26(6):393. doi: 10.1016/j.ccell.2014.11.010

Salmon H, Idovyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity. (2016) 44:924–38. doi: 10.1016/j.immuni.2016.03.012

Roberts EW, Broz ML, Binnewies M, Headley MB, Nelson AE, Wolf DM, et al. Critical role for CD103(+)CD11c(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell. (2016) 30:324–36. doi: 10.1016/j.ccell.2016.06.003

Lou Y, Liu C, Kim GJ, Liu YJ, Hwu P, Wang G. Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses. J Immunol. (2007) 178:1534–41. doi: 10.4049/jimmunol.178.3.1534

Lavin Y, Kobayashi S, Leader A, Amir ED, Elefant N, Bigner WD, et al. Invasive immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell. (2017) 169:795–60 e17. doi: 10.1016/j.cell.2017.04.014

Tang-Hua TL, Gueguen P, Goudot C, Durand M, Bohec M, Baulande S, et al. Human in vivo-generated monocyte-derived dendritic cells and macrophages cross-present antigens through a vascular pathway. Nat Commun. (2018) 9(1):2570. doi: 10.1038/s41467-018-04985-0

Cohn L, Chatterjee B, Esselborn F, Smed-Sorenson A, Nakamura N, Chalouni C, et al. Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation. J Exp Med. (2013) 210:1049–63. doi: 10.1084/jem.20121251

Kretzer NM, Theisen DJ, Tussiwand R, Brisenou CG, Grajales-Reyes GE, Wu X, et al. RAB43 facilitates cross-presentation of cell-associated antigens by CD8α+ dendritic cells. J Exp Med. (2016) 213:2871–83. doi: 10.1084/jem.20160609

Chatterjee B, Smed-Sorenson A, Cohn L, Chalouni C, Vanden R, Lee BC, et al. Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood. (2012) 120:2011–20. doi: 10.1182/blood-2012-01-402370

Allaoui A, Rokkuhein DC, Joannas L, Carpi JC, Iborra S, Magalhaes JG, et al. Critical role for Sec22b-dependent antigen cross-presentation in antitumor immunity. J Exp Med. (2017) 214:2231–41. doi: 10.1084/jem.20170229

Wu SJ, Niknafs YS, Kim SH, Oravecz-Wilson K, Zajac C, Toubai T, et al. A critical analysis of the role of SNARE protein SEC22B in antigen cross-presentation. Cell Rep. (2017) 19:2645–56. doi: 10.1016/j.celrep.2017.06.013

Cebrian I, Visentin G, Blanchard N, Jouve M, Bobard A, Moita C, et al. Sec22b regulates phagosomal maturation and antigen crosspresentation by dendritic cells. Cell. (2011) 147:1355–68. doi: 10.1016/j.cell.2011.11.021

Savina A, Jancic C, Hugues S, Guermounprez V, Pargas V, Moura JC, et al. NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell. (2006) 126:205–18. doi: 10.1016/j.cell.2006.05.035

Mantegazza AR, Savina A, Vermueen M, Perez L, Geffner J, Hermine O, et al. NADPH oxidase controls phagosomal pH and antigen crosspresentation in human dendritic cells. Blood. (2008) 112:4712–22. doi: 10.1182/blood-2008-01-134791

Savina A, Peres A, Cebrian I, Carpi JC, Moita C, Hacohen N, et al. The small GTPase Rac2 controls phagosomal alkalization and antigen...
crosspresentation selectively in CD8(+) dendritic cells. *Immunity.* (2009) 30:544–55. doi: 10.1016/j.immuni.2009.01.013

Janic C, Savina A, Wasmeyer C, Tolmachova T, El-Benna J, Dang PM, et al. Rab27a regulates phagosomal pH and NADPH oxidase recruitment to dendritic cell phagosomes. *Nat Cell Biol.* (2007) 9:367–78. doi: 10.1038/nclb1532i

Ding Y, Guo Z, Liu Y, Li X, Zhang Q, Xu X, et al. The lectin Siglec-G inhibits dendritic cell cross-presentation by impairing MHC class I- peptide complex formation. *Nat Immunol.* (2017) 16:1176–75. doi: 10.1038/nii.3535

Theisen DJ, Davidson JTt, Briseno CG, Gargaro M, Lauron EJ, Wang Q, et al. Rab27a regulates phagosomal pH and NADPH oxidase + doi: 10.1038/ncb1552

Martinez-Lopez M, Iborra S, Conde-Garrosa R, Sancho D. Batf3-dependent CD103+ dendritic cells are major producers of IL-12 that drive local Th1 immunity against Leishmania major infection in mice. *Eur J Immunol.* (2015) 45:119–29. doi: 10.1002/eji.201444651

Everts B, Tussiwand R, Dreesen L, Fairfax KC, Huang SC, Smith AM, et al. Migratory CD103+ dendritic cells suppress helmint-driven type 2 immunity through constitutive expression of IL-12. *J Exp Med.* (2016) 213:35–51. doi: 10.1084/jem.20150235

Hildner K, Edelson BT, Purtha WE, Diamond M, Matsuishi H, Koyama M, et al. Batf3 deficiency reveals a critical role for CD103+ dendritic cells in cytotoxic T cell immunity. *Science.* (2008) 322:1097–100. doi: 10.1126/science.1164206

Byrne KT, Vonderheide RH. CD40 Stimulation obviates innate sensors and drives T cell immunity in cancer. *Cell Rep.* (2016) 15:2719–32. doi: 10.1016/j.celrep.2016.05.058

Spranger S, Dai D, Hortan B, Gajewski TF. Tumor-residing Batf3-dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. *Cancer Cell.* (2017) 31:71–23 e4. doi: 10.1016/j.ccell.2017.04.003

Meyer MA, Baer JM, Knollhoff BL, Nywening TM, Panni RZ, Su X, et al. Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. *Nat Commun.* (2018) 9:1250. doi: 10.1038/s41467-018-03600-6

Sanchez-Paulete AR, Cueto FJ, Martinez-Lopez M, Labiano S, Morales-Kastresana A, Rodriguez-Ruiz ME, et al. Cancer Immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies require BATF3-dependent dendritic cells. *Cancer Discov.* (2016) 6:71–9. doi: 10.1158/2159-8290.CD-15-0510

Li J, Byrne KT, Yan F, Yamazoe T, Chen Z, Baslan T, et al. Tumor immune responses. *Immunol Rev.* (2008) 222:129–44. doi: 11101116-065X.2008.00616.x

Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8(alpha)+ dendritic cells. *J Exp Med.* (2011) 208:2005–16. doi: 10.1084/jem.20101159

Diamond MS, Kinder M, Matsuishi H, Mashayekhi M, Dunn GP, Archambaut JM, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. *J Exp Med.* (2011) 208:1989–2003. doi: 10.1084/jem.20111158

Fontenou JF, Gillet M, Larsson M, Dasilva I, Munz C, Liu YJ, et al. Activation of influenza virus-specific CD4+ and CD8+ T cells: a new role for plasmacytoid dendritic cells in adaptive immunity. *Blood.* (2003) 101:3520–6. doi: 10.1182/blood-2002-10-3063

Tel J, Aarntzen EH, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D, et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. *Cancer Res.* (2013) 73:1063–75. doi: 10.1158/0008-5472.CAN-12-3283

Perez-Cabezas B, Naranjo-Gomez M, Ruiz-Riol M, Bastos-Amador P, Fernandez MA, Carmona E, et al. TLR-activated conventional DCs promote immunosuppressive-conditioned of plasmacytoid DCs. *J Leukoc Biol.* (2012) 92:133–43. doi: 10.1189/jlb.09111452

Nascimbieni M, Perie L, Chororo I, Dioucou S, Kreitmann L, Louis S, et al. Plasmacytoid dendritic cells accumulate in spleens from chronically HIV-infected patients but barely participate in interferon-alpha expression. *Blood.* (2009) 113:6112–9. doi: 10.1182/blood-2008-07-170803

Verma W, Lonardi S, Morassi M, Rossini C, Venturini M, et al. Cutaneous distribution of plasmacytoid dendritic cells in lupus erythematosus. Selective tropism at the site of epithelial apoptotic damage. *Immunobiology.* (2009) 214:877–86. doi: 10.1007/s00785-009.06.018

Rogers GL, Shirley JL, Zolotukhin I, Kumar SRP, Perrin GQ, et al. Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8+ T cells. *Blood.* (2017) 129:3184–95. doi: 10.1182/blood-2016-11-751040

Yoneyama H, Matsuno K, Toda E, Schreibelt G, Nakano A, et al. Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs. *J Exp Med.* (2005) 202:425–35. doi: 10.1084/jem.20041961

Asselin-Paturel C, Boonstra A, Dalod M, Durand I, Yessaud N, Dardenne-Chambon C, et al. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. *Nat Immunol.* (2001) 2:1144–50. doi: 10.1038/7136

Swiecki M, Gillflan S, Verme W, Wang Y, Colonna M. Plasmacytoid dendritic cell ablation impacts early interferon responses and...
antiviral NK and CD8+ T cell accrual. *Immunity.* (2010) 33:955–66. doi: 10.1016/j.immuni.2010.11.020

95. Cervantes-Barragan L, Lewis KL, Firer S, Thiel V, Hugues S, Keith W, et al. Plasmacytoid dendritic cells control T-cell response to chronic viral infection. *Proc Natl Acad Sci USA.* (2012) 109:3012–7. doi: 10.1073/pnas.1117599109

96. Terra M, Oberkampf M, Fayolle C, Rosenbaum P, Guillerey C, Dadaglio G, et al. Tumor-derived TGFBeta alters the ability of plasmacytoid dendritic cells to respond to innate immune signaling. *Cancer Res.* (2018) 78:3014–26. doi: 10.1158/0008-5472.CAN-17-2719

97. Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla JP, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. *Clinical Cancer Res.* (2004) 10:7466–74. doi: 10.1158/1078-0432.CCR-04-0684

98. Conrad C, Gregorio J, Wang YH, Ito T, Meller S, Hanabuchi S, et al. Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3+ T-regulatory cells. *Cancer Res.* (2012) 72:5240–9. doi: 10.1158/0008-5472.CAN-12-2271

99. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. *Nat Rev Immunol.* (2004) 4:762–74. doi: 10.1038/nri1457

100. Kitano M, Yamazaki C, Takami A, Ikeno T, Hemmi H, Takahashi N, et al. Imaging of the cross-presenting dendritic cell subsets in the skin-draining lymph node. *Proc Natl Acad Sci USA.* (2016) 113:10344–9. doi: 10.1073/pnas.1513607113

101. Gerner MY, Kastenmuller W, Ifrim I, Kabat J, Germain RN. Histo-cytometry: a method for highly multiplex quantitative tissue imaging analysis applied to dendritic cell subset microanatomy in lymph nodes. *Immunity.* (2012) 37:364–76. doi: 10.1016/j.immuni.2012.07.011

102. Gerner MY, Casey KA, Kastenmuller W, Germain RN. Dendritic cell and antigen dispersal landscapes regulate T cell immunity. *J Exp Med.* (2017) 214:3105–22. doi: 10.1002/jem.2170335

103. Borst J, Ahrends T, Babala N, Melief CJM, Kastenmuller W. CD4+ T cell help in cancer immunology and immunotherapy. *Nat Rev Immunol.* (2018) 18:635–47. doi: 10.1038/s41577-018-0004-0

104. Calabro S, Liu D, Gallman A, Nascimento MS, Yu Z, Zhang TT, et al. Differential intrasplenic migration of dendritic cell subsets tailors to dendritic cell subset microanatomy in lymph nodes. *Immunity.* (2018) 53:11353. doi: 10.1016/j.immuni.2018.07.021

105. Andre H, Masi D, Alric F, Proux S, Mothe-Pichard C, Trinchieri G, et al. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell subset and generate functional CD8 T cell memory. *Science.* (2003) 300:337–9. doi: 10.1126/science.10582

106. Cervantes-Barragan L, Lewis KL, Firer S, Thiel V, Hugues S, Keith W, et al. Plasmacytoid dendritic cells control T-cell response to chronic viral infection. *Proc Natl Acad Sci USA.* (2012) 109:3012–7. doi: 10.1073/pnas.1117599109

107. Terra M, Oberkampf M, Fayolle C, Rosenbaum P, Guillerey C, Dadaglio G, et al. Tumor-derived TGFBeta alters the ability of plasmacytoid dendritic cells to respond to innate immune signaling. *Cancer Res.* (2018) 78:3014–26. doi: 10.1158/0008-5472.CAN-17-2719

108. Gerner MY, Casey KA, Menser MF. Defective MHC class II presentation by dendritic cells limits CD4+ T cell help for antitumor CD8+ T cell responses. *J Immunol.* (2008) 181:64–4. doi: 10.4049/jimmunol.181.1.155

109. Anderson MJ, Shafer-Weaver K, Greenberg NM, Hurwitz AA. Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. *J Immunol.* (2007) 178:1268–76. doi: 10.4049/jimmunol.178.3.1268

110. Gardner A, Ruffell B. Dendritic cells and cancer immunity. *Trends Immunol.* (2016) 37:855–65. doi: 10.1016/jjit.2016.09.006

111. Zhu Z, Cuss SM, Singh V, Gurusamy D, Shoe JL, Leighty R, et al. CD4+ T cell help selectively enhances high-avidity tumor antigen-specific CD8+ T cells. *J Immunol.* (2015) 195:3482–9. doi: 10.4049/jimmunol.1101571

112. Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. *Cancer Res.* (2010) 70:8368–77. doi: 10.1158/0008-5472.CAN-10-1322

113. Schietinger A, Philip M, Liu RB, Schreiber K, Schreiber H. Bystander killing of cancer requires the cooperation of CD4+ and CD8+ T cells during the effector phase. *J Exp Med.* (2010) 207:2469–77. doi: 10.1084/jem.20092450

114. Alarcon P, Atar S, Pernis B, Avila R, Cornejo F, Rueda A, et al. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. *J Immunol.* (2000) 165:6047–55. doi: 10.4049/jimmunol.165.11.6047

115. Ahrends T, Spanjaard A, Pilzecker B, Babala N, Bovens A, Xiao Y, et al. CD4+ T cell help confers a cytotoxic T cell effector program including co-inhibitory receptor downregulation and increased tissue invasiveness. *Immunity.* (2017) 47:848–61 e5. doi: 10.1016/j.immuni.2017.10.009

116. Gallotta M, Assi H, Degagne E, Kannan SK, Coffman RL, Guiducci C. Inhaled TLR9 agonist renders lungs tumour permissive to PD-1 blockade by promoting optimal CD4+ and CD8+ T-cell Interplay. *Cancer Res.* (2018) 78:4943–56. doi: 10.1158/0008-5472.CAN-18-0729

117. Neubert K, Lehmann CH, Heger L, Baranska A, Staedler AM, Buchholz VR, et al. Antigen delivery to DC11c+CD8+ dendritic cells induces protective immune responses against experimental melanoma in mice in vivo. *J Immunol.* (2014) 192:5830–8. doi: 10.4049/jimmunol.1300975

118. Alonso R, Flament H, Lemoine S, Sedlck C, Bettasso E, Peguillet I, et al. Induction of anergic or regulatory tumor-specific CD4+ T cells in the tumor-draining lymph node. *Nat Commun.* (2018) 9:2113. doi: 10.1038/s41467-018-04524-x

119. Michea P, Noel F, Zakine E, Czerwinska U, Sirven P, Abouzid O, et al. Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific. *Nat Immunol.* (2018) 19:885–97. doi: 10.1038/s41590-018-0145-8

120. Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalinski SR, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. *Nat Commun.* 2016;7:10582. doi: 10.1038/ncomms10582
133. Thompson ED, Enriquez HL, Fu YX, Engelhard VH. Tumor masses support
134. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H,
136. Ali OA, Emerich D, Dranoff G, Mooney DJ. DC Interactions in Cancer
138. Pitzalis C, Jones GW, Bombardieri M, Jones SA. Ectopic lymphoid- like
140. Joshi NS, Akama-Garren EH, Lu Y, Lee DY, Chang GP, Li A, et al.
141. Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, Knockaert S,
148. Bottcher JP, Bonavita E, Chakravarty P, Blees H, Cabezés-Cabezón
149. Ferlazzo G, Pack M, Thomas D, Paludan S, Schmid D, Strowig T,
150. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic
151. Liu C, Lonard DO, Hobart C, Djinovic-Carugo K, Herlyn M, Daves SM,
152. T cells. Cancer Cell. (2014) 26:4410–7. doi: 10.1016/j.cell.2018.
153. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-gamma-
154. Liu C, Lou Y, Lizee G, Qin H, Liu S, Rabinovich R, et al. Plasmacytoid
155. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural
156. Nair S, Dhodapkar MV. Natural killer T cells in cancer immunotherapy.
157. Kobayashi E, Motoki K, Uchida T, Fukushima H, Koezuka Y, Khan CR,
158. Giaccone G. Clinical impact of novel treatment strategies. Oncogene.
159. Parekh VV, Wilson MT, Olivares-Villagómez D, Singh AK, Wu L, Wang CR,
160. King LA, Lameris R, de Gruijl TD, van der Vliet HJ. CD1d-Invariant natural
161. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-gamma-
162. Nair S, Dhodapkar MV. Natural killer T cells in cancer immunotherapy.
163. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic
164. Joshi NS, Akama-Garren EH, Lu Y, Lee DY, Chang GP, Li A, et al. Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses. Immunity. (2015) 43:579–90. doi: 10.1016/j.immuni.2015.08.006
165. Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, Knockaert S, et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytokotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. (2014) 74:705–15. doi: 10.1158/0008-5472.CAN-13-1342
166. Dieu-Nosjean MC, Antoine M, Daniel C, Heudes D, Wislez M, Poulot V, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. (2008) 26:4410–7. doi: 10.1200/JCO.2007.15.0284
167. Remark R, Becker C, Gomez JE, Damotte D, Dieu-Nosjean MC, Sautès-Fridman C, et al. The non-small-cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. Am J Respir Crit Care Med. (2015) 191:377–90. doi: 10.1164/rcrm.201410-1671PP
168. Iang JE, Hadjou CH, Liot C, Miller G, Dustin ML, Bar-Sagi D. Cross-talk between regulatory T cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic cancer. Cell Rep. (2017) 20:558–71. doi: 10.1016/j.celrep.2017.06.062
169. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med. (1999) 5:405–11. doi: 10.1038/7403
170. Borg C, Jallil A, Lederach D, Maruyama K, Wakasugi H, Charrier S, et al. NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood. (2004) 104:3267–75. doi: 10.1182/blood-2004-01-0380
171. Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. (2016) 16:7–19. doi: 10.1038/nrc.2015.5
172. Böttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrero M, Sammicheli S, et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell. (2018) 172:1022–37 e14. doi: 10.1016/j.cell.2018.01.004
173. Ferlazzo G, Pack M, Thomas D, Paludan S, Schmid D, Strowig T, et al. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs.

Proc Natl Acad Sci USA. (2004) 101:16606–11. doi: 10.1073/pnas.0401752101
174. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity. (2007) 26:503–17. doi: 10.1016/j.immuni.2007.09.006
175. Liu C, Lou Y, Lizee G, Qin H, Liu S, Rabinovich R, et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest. (2008) 118:1165–75. doi: 10.1172/JCI33583
176. Godfrey DJ, Uldrich AP, McCluskey J, Rossjohn J, Moody DB. The burgeoning family of unconventional T cells. Nat Immunol. (2015) 16:1114–23. doi: 10.1038/nii.2015.30
177. Fujiwara Y, Yamazaki T, Aymeric L, Yang H, et al. DC Interactions in Cancer
178. Ali OA, Emerich D, Dranoff G, Mooney DJ. DC Interactions in Cancer
179. Thompson ED, Enriquez HL, Fu YX, Engelhard VH. Tumor masses support
180. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H,
181. Pitzalis C, Jones GW, Bombardieri M, Jones SA. Ectopic lymphoid- like
182. Ali OA, Emerich D, Dranoff G, Mooney DJ. DC Interactions in Cancer
183. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-gamma-
184. Liu C, Lonard DO, Hobart C, Djinovic-Carugo K, Herlyn M, Daves SM,
185. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic
186. Nair S, Dhodapkar MV. Natural killer T cells in cancer immunotherapy.
187. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural
188. Fujiwara Y, Yamazaki T, Aymeric L, Yang H, et al. DC Interactions in Cancer
189. Thompson ED, Enriquez HL, Fu YX, Engelhard VH. Tumor masses support
190. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H,
191. Pitzalis C, Jones GW, Bombardieri M, Jones SA. Ectopic lymphoid- like
192. Ali OA, Emerich D, Dranoff G, Mooney DJ. DC Interactions in Cancer
193. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-gamma-
194. Liu C, Lonard DO, Hobart C, Djinovic-Carugo K, Herlyn M, Daves SM,
195. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic
196. Nair S, Dhodapkar MV. Natural killer T cells in cancer immunotherapy.
197. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural
198. Fujiwara Y, Yamazaki T, Aymeric L, Yang H, et al. DC Interactions in Cancer
199. Thompson ED, Enriquez HL, Fu YX, Engelhard VH. Tumor masses support
200. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H,
169. Unanue ER. Antigen-presenting function of the macrophage. *Ann Rev Immunol.* (1984) 2:395–428. doi: 10.1146/annurev.iy.02.040184.002143

170. Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. *Science.* (2014) 343:152–7. doi: 10.1126/science.1246886

171. Tsou P, Katayama H, Ostrin EL, Hanash SM. The Emerging Role of B Cells in Tumor Immunity. *Cancer Res.* (2016) 76:5597–601. doi: 10.1158/0008-5472.CAN-16-0431

172. Yuen GJ, Demissie E, Pillai S. B lymphocytes and cancer: a love-hate relationship. *Trends Cancer.* (2016) 2:747–57. doi: 10.1016/j.trecan.2016.10.010

173. Bekeredjian-Ding IB, Wagner M, Hornung V, Giese T, Schnurr M, Endres S, et al. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. *J Immunol.* (2005) 174:4043–50. doi: 10.4049/jimmunol.174.7.4043

174. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. *Immunity.* (2003) 19:225–34. doi: 10.1016/S1074-7613(03)00208-5

175. Dubois B, Vanbervliet B, Fayette J, Massacrier C, Van Kooten C, Briere F, et al. Dendritic cells enhance growth and differentiation of CD40-activated B lymphocytes. *J Exp Med.* (1997) 185:941–51. doi: 10.1084/jem.185.5.941

176. Germain C, Gnjatic S, Tamzali F, Knockaert S, Remark R, Goc J, et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. *Am J Respir Crit Care Med.* (2014) 189:832–44. doi: 10.1164/rccm.201309-1611OC

177. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. *Nature.* (2015) 523:231–5. doi: 10.1038/nature14404

178. Liu YJ, Soumelis V, Watanabe N, Ito T, Wang YH, Malefyt Rde W, et al. TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. *Ann Rev Immunol.* (2007) 25:193–219. doi: 10.1146/annurev.immunol.25.022106.141718

179. Cheng JT, Deng YN, Yi HM, Wang GY, Fu BS, Chen WJ, et al. Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation. *Oncogenesis.* (2016) 5:e198. doi: 10.1038/oncsis.2016.7

180. Ohshio Y, Teramoto K, Hanaoka J, Tezuka N, Itoh Y, Asai T, et al. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine. *Cancer Sci.* (2015) 106:134–42. doi: 10.1111/cas.12584

181. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. *Immunity.* (2013) 39:38–48. doi: 10.1016/j.immuni.2013.07.004

182. Constantino J, Gomes C, Falcao A, Cruz MT, Neves BM. Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives. *Transl Res.* (2016) 168:74–95. doi: 10.1016/j.trsl.2015.07.008

183. Adema GJ, de Vries IJ, Punt CJ, Figdor CG. Migration of dendritic cell based cancer vaccines: in vivo veritas? *Curr Opin Immunol.* (2005) 17:170–4. doi: 10.1016/j.coi.2005.01.004

Conflict of Interest Statement: RN, SM-M, and KT are full-time employees of Amgen Inc.

Copyright © 2019 Noubade, Majri-Morrison and Tarbell. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.